Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]

This article refers to:

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives

Anagnostou T, Litzow MR. Blood Lymphat Cancer. 2018;8:1–9.

On page 2, Table 1 was incorrectly presented. Table 1 should have been:

Table 1 Inhibition of kinases by different TKIs approved for the treatment of CML and/or ALL

Kinase	Imatinib	Dasatinib	Nilotinib	Bosutinib	Ponatinib
ABL1	X	X	X	X	X
T315I		X		X	X
FGFR		X		X	X
VEGFR				X	X
PDGFR	X	X	X	X	X
KIT	X	X	X		X
FLT3	X			X	X
SRC		X		X	X

Note: Over 50% inhibition is indicated by X.

Abbreviations: ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; TKIs, tyrosine kinase inhibitors; ABL1, abelson murine leukemia viral oncogene homolog 1; FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; KIT, stem cell growth factor receptor; FLT3, fms-like tyrosine kinase 3; SRC, sarcoma kinase.